<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to assess the efficacy and safety of tandospirone, a 5-HT1A partial <z:chebi fb="4" ids="48705">agonist</z:chebi>, for treatment of behavioural and psychological symptoms of <z:hpo ids='HP_0000726'>dementia</z:hpo> (BPSD) </plain></SENT>
<SENT sid="1" pm="."><plain>Thirteen outpatients with <z:chebi fb="4" ids="38624">DSM</z:chebi>-IV diagnosis of Alzheimer's type or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> were enrolled in this study </plain></SENT>
<SENT sid="2" pm="."><plain>Their BPSD and cognitive functions were evaluated with the Neuropsychiatric Inventory (NPI) and Mini-Mental State Examination, respectively, for an 8-wk period of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>The maximum benefit of tandospirone was achieved at a mean dose of 19.6 mg/d </plain></SENT>
<SENT sid="4" pm="."><plain>There were significant improvements in the NPI subscores for <z:e sem="disease" ids="C0011253" disease_type="Mental or Behavioral Dysfunction" abbrv="">delusion</z:e>, <z:hpo ids='HP_0000713'>agitation</z:hpo>, <z:hpo ids='HP_0000716'>depression</z:hpo>, <z:hpo ids='HP_0000739'>anxiety</z:hpo>, and <z:hpo ids='HP_0000737'>irritability</z:hpo> at 2 or 4 wk after the start of administration of tandospirone </plain></SENT>
<SENT sid="5" pm="."><plain>No patients experienced severe adverse effects </plain></SENT>
<SENT sid="6" pm="."><plain>The results suggest that tandospirone was effective at improving BPSD symptoms and well-tolerated in elderly <z:e sem="disease" ids="C0860630" disease_type="Mental or Behavioral Dysfunction" abbrv="">demented</z:e> patients </plain></SENT>
</text></document>